PerformanceResearch Phase

IGF-1 LR3 (Long-Arg3)

Subcutaneous injection

Overview

IGF-1 LR3 is a synthetic analogue of insulin-like growth factor 1 with an N-terminal extension of 13 amino acids and a substitution of arginine for glutamic acid at position 3. These modifications reduce binding to IGF-binding proteins, resulting in an extended half-life and increased bioavailability compared to native IGF-1.

Mechanism of Action

The peptide promotes anabolic processes including muscle protein synthesis, glucose uptake, and cellular proliferation. IGF-1 LR3 is not approved for human use and is primarily available as a research reagent, though it is sometimes misused in athletic and bodybuilding contexts..

Research Summary & Key Findings

No clinical trials have evaluated IGF-1 LR3 for safety or efficacy in humans, and the compound is not approved by the FDA or other major regulatory agencies. Preclinical studies demonstrate potent anabolic and mitogenic effects in cell culture and animal models. The absence of human pharmacokinetic, safety, and controlled efficacy data, combined with concerns about mitogenic risks and off-label misuse, restricts IGF-1 LR3 to experimental research applications.

Clinical Status

Research Phase

IGF-1 LR3 (Long-Arg3) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injection

Related Peptides in Performance

Find a Provider

Find a verified provider who offers IGF-1 LR3 (Long-Arg3) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply IGF-1 LR3 (Long-Arg3).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.